| Title |
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, December 2013
|
| DOI | 10.1007/s00280-013-2359-7 |
| Pubmed ID | |
| Authors |
Muhammad Wasif Saif, Jia Li, Lynne Lamb, Kristin Kaley, Kyle Elligers, Zaoli Jiang, Scott Bussom, Shwu-Huey Liu, Yung-Chi Cheng |
| Abstract |
Preclinical studies showed a Chinese botanical formula, PHY906, has synergistic anti-tumor activity with capecitabine. Our phase I study determined maximal tolerated dose of capecitabine 1,500 mg/m(2) BID day 1-7 and PHY906 800 mg BID day 1-4 every 2 weeks. We conducted this phase II study to explore the efficacy of capecitabine and PHY906 in patients with advanced pancreatic cancer who were previously treated with gemcitabine-based regimens. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Unknown | 61 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 15% |
| Researcher | 7 | 11% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Bachelor | 6 | 10% |
| Other | 6 | 10% |
| Other | 10 | 16% |
| Unknown | 17 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 24% |
| Agricultural and Biological Sciences | 6 | 10% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Nursing and Health Professions | 4 | 6% |
| Unspecified | 2 | 3% |
| Other | 8 | 13% |
| Unknown | 22 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 December 2013.
All research outputs
#16,049,105
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#1,859
of 2,501 outputs
Outputs of similar age
#197,836
of 311,568 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#18
of 23 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 20th percentile – i.e., 20% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 311,568 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.